EGFR and neoplasm: A phase I clinical trial (NCT02369198 [99]) using an epidermal growth factor receptor (EGFR) antibody-coated bacterial-derived minicell system loaded with miR-16 mimic (MesomiR-1) showed an effective inhibition of tumor growth.